Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment
BackgroundThe increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2024-12-01
|
| Series: | Frontiers in Endocrinology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fendo.2024.1407692/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846118210729934848 |
|---|---|
| author | Chiao-Ling Chen Jian-Ying Wang |
| author_facet | Chiao-Ling Chen Jian-Ying Wang |
| author_sort | Chiao-Ling Chen |
| collection | DOAJ |
| description | BackgroundThe increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative efficacy and safety profiles.MethodsWe conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. Our analysis included randomized controlled trials (RCTs) comparing denosumab with bisphosphonates in GIOP management. The outcomes were percent changes in bone mineral density (BMD) at various sites, bone turnovers markers (BTMs) and the incidence of adverse events.ResultsOur study comprised five RCTs with 1,043 participants. The results showed a significant mean difference in BMD percentage change from baseline at LS of 2.87% (95% CI: 1.86 to 3.87, p<0.001) and at TH of 1.39% (95% CI: 0.15 to 2.64, p=0.03). Additionally, the safety profile of denosumab was found to be comparable to bisphosphonates, with no significant increase in the incidence of adverse events or serious adverse reactions.ConclusionsDenosumab proved more effective in enhancing BMD than bisphosphonates in GIOP, maintaining a comparable safety profile. However, the study’s limitations, including heterogeneity and the need for longer-term research, were noted. |
| format | Article |
| id | doaj-art-d97bc18af4d34becb0ddb4502365e01d |
| institution | Kabale University |
| issn | 1664-2392 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Endocrinology |
| spelling | doaj-art-d97bc18af4d34becb0ddb4502365e01d2024-12-18T05:10:36ZengFrontiers Media S.A.Frontiers in Endocrinology1664-23922024-12-011510.3389/fendo.2024.14076921407692Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessmentChiao-Ling Chen0Jian-Ying Wang1Department of Pharmacy, Taipei City Hospital, Taipei, TaiwanDepartment of Pharmacy, New Taipei City Hospital, New Taipei City, TaiwanBackgroundThe increasing prevalence of glucocorticoid-induced osteoporosis (GIOP) due to long-term glucocorticoid therapy underscores the need for effective treatment options. Denosumab and bisphosphonates, both key in managing GIOP, require further comparative evaluation to determine their relative efficacy and safety profiles.MethodsWe conducted a systematic review and meta-analysis, adhering to PRISMA guidelines. Our analysis included randomized controlled trials (RCTs) comparing denosumab with bisphosphonates in GIOP management. The outcomes were percent changes in bone mineral density (BMD) at various sites, bone turnovers markers (BTMs) and the incidence of adverse events.ResultsOur study comprised five RCTs with 1,043 participants. The results showed a significant mean difference in BMD percentage change from baseline at LS of 2.87% (95% CI: 1.86 to 3.87, p<0.001) and at TH of 1.39% (95% CI: 0.15 to 2.64, p=0.03). Additionally, the safety profile of denosumab was found to be comparable to bisphosphonates, with no significant increase in the incidence of adverse events or serious adverse reactions.ConclusionsDenosumab proved more effective in enhancing BMD than bisphosphonates in GIOP, maintaining a comparable safety profile. However, the study’s limitations, including heterogeneity and the need for longer-term research, were noted.https://www.frontiersin.org/articles/10.3389/fendo.2024.1407692/fulldenosumabbisphosphonatesglucocorticoid-induced osteoporosisbone mineral densitymeta-analysis |
| spellingShingle | Chiao-Ling Chen Jian-Ying Wang Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment Frontiers in Endocrinology denosumab bisphosphonates glucocorticoid-induced osteoporosis bone mineral density meta-analysis |
| title | Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment |
| title_full | Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment |
| title_fullStr | Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment |
| title_full_unstemmed | Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment |
| title_short | Superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid-induced osteoporosis: a systematic review and meta-analysis with GRADE quality assessment |
| title_sort | superiority of denosumab over bisphosphonates in preventing and treating glucocorticoid induced osteoporosis a systematic review and meta analysis with grade quality assessment |
| topic | denosumab bisphosphonates glucocorticoid-induced osteoporosis bone mineral density meta-analysis |
| url | https://www.frontiersin.org/articles/10.3389/fendo.2024.1407692/full |
| work_keys_str_mv | AT chiaolingchen superiorityofdenosumaboverbisphosphonatesinpreventingandtreatingglucocorticoidinducedosteoporosisasystematicreviewandmetaanalysiswithgradequalityassessment AT jianyingwang superiorityofdenosumaboverbisphosphonatesinpreventingandtreatingglucocorticoidinducedosteoporosisasystematicreviewandmetaanalysiswithgradequalityassessment |